August 13, 2018

Ibrutinib is now approved in the USA for all indications for chronic lymphocytic leukemia. That hasn’t always been the case. Its first approval was more limited. In fact, the first approval was not in CLL, but in its sister cancer with arguably an ever even greater need for more